February 2007:
February 27th:
Pro Medicus Continues Record Profit Growth
read article >
February 23rd:
Pharmaxis' Phase III Cystic Fibrosis Study Closes Enrollment
read article >
February 23rd:
Biosignal Investor Update
read article >
February 22nd:
Heart Failure Experts Appointed As Co-Principal Investigators for Sunshine Heart's United States Feasibility Trial
read article >
February 22nd:
Pharmaxis Files U.S. Shelf Registration Statement
read article >
February 22nd:
Clinuvel Reports First Positive Phase II Clinical Trial Results Of CUV1647
read article >
February 22nd:
Former Pfizer Vice-President Of Clinical Research Joins Phylogica Board
read article >
February 21st:
Progen Ends Half Year Prepared To Bolster Financial Foundation For PI-88 Registration
read article >
February 21st:
Bone's Proactive Arthritic Drug Attacks The Cause Of Arthritic Pain
read article >
February 21st:
Bionomics Takes Key Steps Forward In The Development Of Anti-Cancer Drug
read article >
February 19th:
Starpharma's DNT And EMD Biosciences Sign siRNA And DNA Reagent License And Supply Agreement
read article >
February 19th:
pSivida Announces A$11.5m (US$9m) Placement
read article >
February 14th:
Clinical Data Supports Development of ChemGenex's Ceflatonin® in Combating Chronic Myeloid Leukemia
read article >
February 13th:
NIH Funds Further Clinical Development of VivaGel™
read article >
February 13th:
Prima BioMed Secures Worldwide Rights To The Commercialisation Of CVac™
read article >
February 13th:
Neuren Pharmaceuticals' NNZ-2566 Receives Further Validation as a Traumatic Brain Injury Treatment
read article >
February 9th:
Cytopia Half Year Report: Excellent Progress Across All Programs
read article >
February 8th:
ChemGenex Announces New Significant Investors, Completes Capital Raising, Announces Rights Issue and Board Changes
read article >
February 7th:
Sunshine Heart Announces Change of Chief Financial Officer
read article >
February 6th:
Solbec's Rhamnose Binding Protein Paten Granted In New Zealand
read article >
February 6th:
New Non-Executive Director
read article >
February 5th:
Progen SPP Exceeds Expectations With $5.4 Million Raised
read article >
February 1st:
VivaGel™ Clinical Trials Proceeding as Planned - Statement on CS Trial Closure
read article >
February 1st:
Phase III Bronchitol Clinical Trial Fully Recruited
read article >
February 1st:
CogState Signs its First Agreement with Abbott
read article >
|
